ClinicalTrials.gg
Active, not recruitingNCT06101134Updated Sep 14, 2026Results posted

A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations

A Phase 2 interventional study of relatlimab+nivolumab and relatlimab+nivolumab+rHuPH20 in Melanoma, sponsored by Bristol-Myers Squibb. Active, not recruiting at 31 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-14.

Sponsored by Bristol-Myers Squibb · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
100
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies testing relatlimab in Melanoma — 6 open to participants now, 10 under way, 1 of them phase 3. relatlimab · Melanoma.

Enrollment
4th of 16
100 · median 48
Started
2023
with 4 others
Phase 2
10 of 16
4 open now
Registered
11th of 16
by date
Lead sponsor
5 of 16
Bristol-Myers Squibb

Among the 16 studies testing relatlimab in Melanoma, this one is the 4th largest by enrollment, is one of 5 that started in 2023, is one of 10 in phase 2, and was the 11th registered.

Melanoma

3,373 studies on the registry are indexed under Melanoma; 580 are open to participants now.

Browse Melanoma studies →

Open to participants now

6 of the 16 studies testing relatlimab in Melanoma are open now, in 2 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About relatlimab

relatlimab: first FDA approval 2022 (OPDUALAG), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 467 Melanoma studies recruiting now, 380 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing relatlimab in Melanoma, or all of them as a file.
02

Study summary

The purpose of this study is to assess the patient's preference for nivolumab subcutaneous (SC) or nivolumab + relatlimab fixed-dose combination (FDC) SC and provide patient experience data by route of administration. This study will also generate safety data which will further characterize the safety profile of patients switching the route of administration from intravenous (IV) to SC.

03

Conditions studied

  • Melanoma

Keywords

  • Patient preference
  • Nivolumab Relatlimab IV
  • Nivolumab Relatimab SC
  • Melanoma
  • rHuPH20
  • FDC IV
  • FDC SC
  • Adjuvant
  • Metastatic
  • Switch
  • Nivolumab
  • Relatlimab
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must have either melanoma and have not had previous treatment for their cancer, or resected melanoma and have had the cancer removed fully with surgery no later than 12 weeks before the start of treatment and confirmed free of disease
  • Must have a low level of disability and cancer that is considered advanced for metastatic melanoma and at risk for becoming advanced (intermediate) or advanced for resected melanoma

Exclusion criteria

Exclusion Criteria:

  • Must not have any brain cancer/disease treated with radiation, any cancer in the eyes or mucous membranes (cells that cover inside surface of parts of the body and keep it moist), any disease, or any condition that is being treated with for inflammation (corticosteroids) or medication to decrease the body's immune system response ( drugs)

Other protocol-defined inclusion/exclusion criteria apply.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (actual)

Study arms

  • Experimental
    Cohort 1: Metastatic Melanoma

    Drug: relatlimab+nivolumab · Drug: relatlimab+nivolumab+rHuPH20

  • Experimental
    Cohort 2: Resected Melanoma

    Drug: nivolumab · Drug: nivolumab+rHuPH20

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Evaluable Participants That Prefer SC Route of Administration Using the Patient Experience and Preference Questionnaire (PEPQ) (Question 7) After Cycle 4 Day 1 Dose

    PEPQ included 7 items 1. Pain or Discomfort (rated on 1 to 10 scale), 2. Length of time related to administration 3. Length of time related to administration impact amount of time to speak to doctor or nurse about illness or concern 4. Length of time for administration impact time to interact or socialize with other individuals 5. Convenience 6. Satisfaction 7. Choice of which route of administration would be preferred. 95% CI exact confidence interval was reported.

    Time frame: Cycle 4 Day 1 (each cycle consist of 4 weeks)

Secondary outcomes

  1. Number of Participants With Adverse Events and Deaths

    An adverse event is any untoward medical occurrence that begins or worsens after the first dose of study treatment, including any unfavorable sign, symptom, disease, or abnormal lab finding, whether or not related to the product, and may include worsening of pre-existing conditions. A Serious Adverse Event (SAE) is any untoward medical occurrence that results in death, is life-threatening, requires or prolongs hospitalization, causes persistent or significant disability/incapacity, leads to a congenital anomaly/birth defect, or is considered an important medical event requiring intervention to prevent these outcomes.

    Time frame: First dose (Day 1) and 30 days after last dose of study therapy (up to approximately 16 months)

  2. Number of Participants With Laboratory Abnormalities and Immune Mediate Adverse Event

    Time frame: From first dose (Day 1) and up to study completion (up to approximately 45 months)

07

Results

Posted Apr 9, 2026

Participant flow

Participant flow — Overall Study
MilestoneCohort 1: Metastatic MelanomaCohort 2: Resected Melanoma
Started5050
Completed04
Not completed5046
Withdrew: Ongoing treatment2337
Withdrew: Withdrawal by subject11
Withdrew: Progressive disease183
Withdrew: Death10
Withdrew: Adverse event74
Withdrew: Other reasons01

Outcome measures

PrimaryPercentage of Evaluable Participants That Prefer SC Route of Administration Using the Patient Experience and Preference Questionnaire (PEPQ) (Question 7) After Cycle 4 Day 1 Dose

PEPQ included 7 items 1. Pain or Discomfort (rated on 1 to 10 scale), 2. Length of time related to administration 3. Length of time related to administration impact amount of time to speak to doctor or nurse about illness or concern 4. Length of time for administration impact time to interact or socialize with other individuals 5. Convenience 6. Satisfaction 7. Choice of which route of administration would be preferred. 95% CI exact confidence interval was reported.

Time frame:
Cycle 4 Day 1 (each cycle consist of 4 weeks)
Reported as:
Number · percentage of partcipants
Percentage of Evaluable Participants That Prefer SC Route of Administration Using the Patient Experience and Preference Questionnaire (PEPQ) (Question 7) After Cycle 4 Day 1 Dose
percentage of partcipantsCohort 1: Metastatic MelanomaCohort 2: Resected Melanoma
Percentage of Evaluable Participants That Prefer SC Route of Administration Using the Patient Experience and Preference Questionnaire (PEPQ) (Question 7) After Cycle 4 Day 1 Dose78.0 (62.4 to 89.4)70.8 (55.9 to 83.0)
SecondaryNumber of Participants With Adverse Events and Deaths

An adverse event is any untoward medical occurrence that begins or worsens after the first dose of study treatment, including any unfavorable sign, symptom, disease, or abnormal lab finding, whether or not related to the product, and may include worsening of pre-existing conditions. A Serious Adverse Event (SAE) is any untoward medical occurrence that results in death, is life-threatening, requires or prolongs hospitalization, causes persistent or significant disability/incapacity, leads to a congenital anomaly/birth defect, or is considered an important medical event requiring intervention to prevent these outcomes.

Time frame:
First dose (Day 1) and 30 days after last dose of study therapy (up to approximately 16 months)
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events and Deaths
ParticipantsCohort 1: Metastatic MelanomaCohort 2: Resected Melanoma
Adverse Events4747
Serious Adverse Events165
Drug related Adverse Events4036
Adverse events leading to discontinuation35
Injection or infusion related adverse events1414
Deaths00
Other Events of Special Interest - Myasthenic syndrome10
SecondaryNumber of Participants With Laboratory Abnormalities and Immune Mediate Adverse Event
Time frame:
From first dose (Day 1) and up to study completion (up to approximately 45 months)

Results for this outcome have not been posted.

Adverse events

Collected over AE, SAEs and all cause mortality was collected from first dose (Day 1) until primary completion date (up to approximately 17 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1: Metastatic Melanoma8/50 (16%)21/50 (42%)44/50 (88%)
Cohort 2: Resected Melanoma2/50 (4%)6/50 (12%)41/50 (82%)
Most frequent serious events
Showing 10 of 34
Most frequent serious events
EventCohort 1: Metastatic MelanomaCohort 2: Resected Melanoma
Adrenal insufficiencyEndocrine disorders2/500/50
Acute kidney injuryRenal and urinary disorders2/500/50
Pleural effusionRespiratory, thoracic and mediastinal disorders2/500/50
Cardiac arrestCardiac disorders1/500/50
Immune-mediated hyperthyroidismEndocrine disorders0/501/50
Abdominal painGastrointestinal disorders1/500/50
AscitesGastrointestinal disorders1/500/50
ConstipationGastrointestinal disorders0/501/50
DiarrhoeaGastrointestinal disorders1/500/50
Intestinal obstructionGastrointestinal disorders1/500/50
Most frequent other events
Showing 10 of 39
Most frequent other events
EventCohort 1: Metastatic MelanomaCohort 2: Resected Melanoma
ArthralgiaMusculoskeletal and connective tissue disorders11/5016/50
FatigueGeneral disorders14/507/50
DiarrhoeaGastrointestinal disorders10/5013/50
AstheniaGeneral disorders12/5010/50
HypothyroidismEndocrine disorders10/506/50
NauseaGastrointestinal disorders10/504/50
PruritusSkin and subcutaneous tissue disorders8/5010/50
Decreased appetiteMetabolism and nutrition disorders8/502/50
PyrexiaGeneral disorders6/502/50
Abdominal painGastrointestinal disorders4/505/50

Baseline characteristics

Age, Customized
Age, Customized(Participants)Cohort 1: Metastatic MelanomaCohort 2: Resected MelanomaTotal
< 65262248
>= 65242852
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1: Metastatic MelanomaCohort 2: Resected MelanomaTotal
Female192847
Male312253
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Cohort 1: Metastatic MelanomaCohort 2: Resected MelanomaTotal
HISPANIC OR LATINO31114
NOT HISPANIC OR LATINO403979
NOT REPORTED707
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Cohort 1: Metastatic MelanomaCohort 2: Resected MelanomaTotal
White425092
Asian101
Not reported707
08

Study locations

31 sites
  • Local Institution - 0007
    Anchorage, Alaska 99508-2974, United States
  • Local Institution - 0013
    Phoenix, Arizona 85054-4502, United States
  • Local Institution - 0010
    San Francisco, California 94115-3010, United States
  • Local Institution - 0034
    Atlanta, Georgia 30342, United States
  • Local Institution - 0032
    Edgewood, Kentucky 41017, United States
  • Local Institution - 0028
    Albuquerque, New Mexico 87106, United States
  • Local Institution - 0037
    Edmonds, Washington 98026-8032, United States
  • Local Institution - 0036
    Issaquah, Washington 98026, United States
  • Local Institution - 0030
    Seattle, Washington 98104, United States
  • Local Institution - 0015
    Las Condes, Santiago Metropolitan 8331010, Chile
  • Local Institution - 0005
    Concepción, 4070196, Chile
  • Local Institution - 0019
    Thessaloniki, B 546 22, Greece
  • Local Institution - 0014
    Athens, I 115 27, Greece
  • Local Institution - 0029
    Marousi, I 151 25, Greece
  • Local Institution - 0023
    Holargos, Athens, 155 62, Greece
  • Local Institution - 0008
    Piraeus, 185 47, Greece
  • Local Institution - 0033
    Thessaloniki, 564 29, Greece
  • Local Institution - 0017
    Bergamo, BG 24127, Italy
  • Local Institution - 0035
    Meldola, FC 47014, Italy
  • Local Institution - 0018
    Milan, MI 20141, Italy
  • Local Institution - 0012
    Padova, PD 35128, Italy
  • Local Institution - 0021
    Roma, RM 00144, Italy
  • Local Institution - 0004
    Torino, TO 10126, Italy
  • Local Institution - 0026
    Naples, 80131, Italy
  • Local Institution - 0011
    Barcelona, B 08025, Spain
  • Local Institution - 0022
    Barcelona, B 08908, Spain
  • Local Institution - 0009
    Cartagena, MU 30120, Spain
  • Local Institution - 0020
    Badalona, 08916, Spain
  • Local Institution - 0027
    Cantabria, 39008, Spain
  • Local Institution - 0003
    San Pedro Alcántara, Málaga, 10002, Spain
  • Local Institution - 0006
    Seville, 41013, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See Plan Description

Access criteria: See Plan Description

Data sharing details ↗ · www.bms.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2023 to primary completion in Apr 2025, 17 months.

Results were first posted in Apr 2026, 11 months after primary completion.

Of 106 industry-sponsored phase 2 interventional studies under Melanoma, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 60. This study's 17 months is below that.

Counting every sponsor, half of 384 studies reached it within 53 months; a quarter within 32 and three quarters within 90.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 20, 2023
First posted
Oct 26, 2023
StartActual
Nov 6, 2023
Primary completionActual
Apr 10, 2025
CompletionEst.
Dec 21, 2026
Results first posted
Apr 9, 2026
Last update
Sep 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06101134
Responsible party
Sponsor
First posted
Oct 26, 2023
Start date
Nov 6, 2023
Primary completion
Apr 10, 2025
Completion
Dec 21, 2026 (estimated)
Results posted
Apr 9, 2026
Last update
Sep 14, 2026

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Relatlimab · Nivolumab · Hyaluronidase (human recombinant)

Start the discussion